NewslettersHuman Immunology News Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy By Danielle Corrigan - May 16, 2022 0 Travere Therapeutics, Inc. announced the US FDA has accepted and granted Priority Review of its New Drug Application under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy. [Travere Therapeutics, Inc.] Press Release